Where does ImmunoGenesis's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across ImmunoGenesis's 1 recorded funding rounds.

Premier Alternatives

ImmunoGenesis

Houston, TX · Founded 2019 · Privately Held (backing)

Developer of immuno-oncology therapeutics designed to create cold tumor treatments. ImmunoGenesis is based in Houston, TX and was founded in 2019. It was valued at $142 million at its later-stage round in May 2025, the last priced event on record. It has raised $67.2 million across 1 recorded round; the latest was a $44.4 million early-stage round in Mar 2024.

PMV mark · valuation

$142.0M

Oct 2026

Priced at

its later-stage round

May 2025

Total raised

$67.2M

Last round

Early Stage VC

Mar 2024

Cap table — not yet on record

ImmunoGenesis's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Free account

More of ImmunoGenesis with a free account

·The complete investor list: 13 names
·Watch ImmunoGenesis: the Monday email on marks, rounds and moves

Create free account

No card required

Membership and data by Private Market View

Frequently asked about ImmunoGenesis

Where does ImmunoGenesis's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across ImmunoGenesis's 1 recorded funding rounds.